The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Privately-held French drugmaker Servier has announced a trial miss for its cancer med Lonsurf (trifluridine/tipiracil), which is being tested in combination with bevacizumab in colorectal cancer. 22 October 2021
Japanese drug major Chugai Pharmaceutical today announced its decision to construct a new manufacturing building (UK4), in the Ukima Site (Kita-ku, Tokyo), for active pharmaceutical ingredients (APIs) of biopharmaceuticals for early clinical trials. 22 October 2021
A Phase III trial evaluating Dupixent (dupilumab) in adults with uncontrolled prurigo nodularis has met its primary and all key secondary endpoints. 22 October 2021
US clinical-stage drug developer Sio Gene Therapies has presented positive interim data from its ongoing Phase I/II study of AXO-AAV-GM1, its adeno-associated viral vector (AAV)9-based gene therapy candidate for the treatment of GM1 gangliosidosis. 22 October 2021
Rare diseases specialist Swedish Orphan Biovitrum, also known as Sobi, today posted financial results for the third quarter of 2021, with total revenue of 3,761 million Swedish kronor ($437 million), an increase of 27% compared with the same period a year ago and 29% at constant exchange rates (CER). 22 October 2021
Massachusetts, USA-based biotech Selecta Biosciences today announced a strategic licensing agreement to advance a next-generation IgG protease with Genovis, a Swedish enzyme technology company. 21 October 2021
Pushing forward Japan's effort to locally develop COVID-19 shots, Daiichi Sankyo has announced progress on the development of DS-5670, an mRNA vaccine in Japan, being evaluated against the novel coronavirus infectious disease (COVID-19), including results from a Phase I/II clinical trial. 21 October 2021
UK health technology assessor the National Institute for Heath and Care Excellence (NICE) has recommending the use of Givlaari (givosiran) on the NHS in England as an option for the treatment of acute hepatic porphyria (AHP) in people 12 years and older who have clinically confirmed severe recurrent attacks (four attacks or more within 12 months). 21 October 2021
The US Food and Drug Administration has approved Dupixent (dupilumab) as an add-on maintenance treatment of patients aged six to 11 years with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid-dependent asthma. 21 October 2021
Semglee (insulin glargine-yfgn), an insulin glargine biosimilar developed by Indian company Biocon, has been listed as a preferred brand by one of the USA’s largest pharmacy benefit managers, Express Scripts. 21 October 2021
Parisian drugmaker Ipsen has reported total sales of 727 million euros (846 million) in the third quarter, representing growth of 14.9% from the same period of 2020. 21 October 2021
The prevalence of major depressive disorder (MDD) – a highly debilitating condition often known as clinical depression - is expected to increase due to COVID-19-related stress. 21 October 2021
Austrian drug developer Marinomed Biotech has entered a new collaboration and licensing agreement with Chinese drugmaker Luoxin Pharmaceutical Group. 21 October 2021
Looking ahead to the potential implications of Biogen’s landmark approval in Alzheimer’s (AD), industry analyst GlobalData has conducted research into the market potential for a next-generation candidate. 21 October 2021
The US Food and Drug Administration said yesterday that it has taken action to expand the use of a booster dose for COVID-19 vaccines in eligible populations for vaccine developed by Johnson & Johnson and Moderna. 21 October 2021
Dutch biotech VarmX has been awarded up to 17.5 million ($20.4million) from the European Innovation Council (EIC) Accelerator, subject to negotiation, to upscale and accelerate cost effective manufacturing of its lead compound, VMX-C001. 21 October 2021
UK and USA-based clinical stage biotech F-star Therapeutics today announced a license and collaboration agreement with Janssen Biotech, a subsidiary of US healthcare giant of Johnson & Johnson. 20 October 2021
The US medicines cost watchdog the Institute for Clinical and Economic Review (ICER) today released a Final Evidence Report assessing the comparative clinical effectiveness and value of eculizumab and efgartigimod for the treatment of generalized myasthenia gravis (gMG). 20 October 2021
Biogen’s novel Alzheimer’s (AD) therapy is struggling to clear the launch pad, generating just $300,000 in the first quarter in which it became available. 20 October 2021